Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for Global Development and Commercialization of Novel GLP-1-Independent Obesity Candidate HM17321

August 30, 2026

Pharmaceutical Executive Daily Global

Overview

Hanmi Pharm has signed an exclusive, global licensing agreement with Genentech, a Roche Group member, for the worldwide development, manufacturing, and commercialization of HM17321, a novel metabolic therapeutic candidate, valued at up to $2.3 billion. HM17321 targets obesity and related diseases with a unique approach distinct from GLP-1, aiming to improve body composition. This major deal validates Hanmi Pharm’s innovative pipeline and leverages Genentech’s global development and commercialization capabilities, significantly increasing HM17321’s potential to enter the market as a new obesity treatment. This represents a crucial advancement for patients seeking alternative approaches to existing therapies.

In Depth

Key Findings

South Korean pharmaceutical company Hanmi Pharm has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, for the worldwide development, manufacturing, and commercialization of its novel metabolic therapeutic candidate, HM17321. This substantial deal, valued at up to $2.3 billion including upfront and milestone payments, underscores the high international recognition of Hanmi Pharm’s innovative research and development capabilities.

Technical / Clinical Details

HM17321 is a novel drug candidate targeting obesity and related metabolic diseases, distinguished by its mechanism of action which is different from the GLP-1 (Glucagon-like peptide-1) pathway. This drug aims to improve body composition by acting through specific receptors, setting it apart from existing obesity treatments. This distinct mechanism of action holds potential as a new therapeutic option for patients who do not respond to GLP-1 receptor agonists or those seeking a different side effect profile. Genentech will lead the global development of this drug, while Hanmi Pharm may contribute by sharing research data and participating in specific manufacturing processes as part of the co-development.

Background & Context

The global obesity epidemic continues to grow, driving an extremely high demand for effective and safe treatment options. While GLP-1 receptor agonists currently dominate the market, therapies with different mechanisms, such as Hanmi Pharm’s HM17321, are expected to play a crucial role in diversifying the market and addressing varied patient needs. The substantial investment from a major player like Genentech indicates that HM17321 is perceived as having significant market potential. This partnership also contributes to enhancing the global presence of South Korean biotechnology companies.

Strategic Significance & Outlook

Through the partnership with Genentech, HM17321 gains opportunities for rapid global development and commercialization. This includes conducting large-scale clinical trials, seeking approvals from global regulatory authorities, and executing effective market launches. If HM17321 successfully navigates clinical development and gains approval, it will diversify the paradigm of obesity treatment and offer more choices to patients. This agreement serves as a prime example of how innovation from emerging markets, combined with the global reach of established pharmaceutical giants, can accelerate drug discovery, potentially setting a model for future industry collaborations.

Source: https://www.pharmexec.com/view/hanmi-pharm-2-billion-licensing-genentech-hm17321

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.